Faster turnaround for breast cancer test:
This article was originally published in Clinica
Executive Summary
Ortho-Clinical Diagnostics has added a new test for monitoring breast cancer to its fully-automated VITROS ECi immunodiagnostic system. The Raritan, New Jersey based company has incorporated into its system Centocor Diagnostic's CA 15-3 assay for monitoring the breast cancer marker DF3-defined antigen in patients following surgery and during radiation or chemotherapy. Running the assay on the ECi system can produce results in as little as 43 minutes, said Ortho.